JP2009536156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536156A5 JP2009536156A5 JP2009505499A JP2009505499A JP2009536156A5 JP 2009536156 A5 JP2009536156 A5 JP 2009536156A5 JP 2009505499 A JP2009505499 A JP 2009505499A JP 2009505499 A JP2009505499 A JP 2009505499A JP 2009536156 A5 JP2009536156 A5 JP 2009536156A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- formula
- hydrogen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- -1 chloro, bromo, amino, substituted amino Chemical group 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 2
- 0 C*N(*)C(C)=O Chemical compound C*N(*)C(C)=O 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000031995 Gorlin syndrome Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029600 embryonic pattern specification Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000004470 heterocyclooxy group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000008410 smoothened signaling pathway Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79216206P | 2006-04-14 | 2006-04-14 | |
| PCT/US2007/009138 WO2007120827A2 (en) | 2006-04-14 | 2007-04-12 | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536156A JP2009536156A (ja) | 2009-10-08 |
| JP2009536156A5 true JP2009536156A5 (enExample) | 2011-05-26 |
Family
ID=38474269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505499A Withdrawn JP2009536156A (ja) | 2006-04-14 | 2007-04-12 | ヘッジホッグ経路関連障害の処置におけるビアリールカルボキサミドの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090306149A1 (enExample) |
| EP (1) | EP2010170A2 (enExample) |
| JP (1) | JP2009536156A (enExample) |
| KR (1) | KR20090006089A (enExample) |
| CN (1) | CN101420949A (enExample) |
| AU (1) | AU2007238676A1 (enExample) |
| BR (1) | BRPI0710723A2 (enExample) |
| CA (1) | CA2648196A1 (enExample) |
| MX (1) | MX2008013204A (enExample) |
| RU (1) | RU2008144805A (enExample) |
| WO (1) | WO2007120827A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| ES2610130T3 (es) | 2007-12-27 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Métodos para reducción estereoselectiva |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| AU2009217982B2 (en) * | 2008-02-26 | 2013-04-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| CA2735177C (en) | 2008-08-29 | 2014-03-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Saturated bicyclic heterocyclic derivatives as smo antagonists |
| JP5773873B2 (ja) * | 2008-10-01 | 2015-09-02 | ノバルティス アーゲー | ヘッジホッグ経路関連障害の治療のためのスムースンド拮抗作用 |
| ES2567134T3 (es) | 2009-08-05 | 2016-04-20 | Infinity Pharmaceuticals, Inc. | Transaminación enzimática de análogos de ciclopamina |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| FR2967498B1 (fr) * | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | Utilisation de derives de quinolinone comme outil de recherche |
| DK2663309T3 (en) | 2011-01-10 | 2017-06-19 | Infinity Pharmaceuticals Inc | METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| EP2925363A4 (en) | 2012-11-29 | 2016-11-09 | Strasspharma Llc | METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US20170231968A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| IL263680B2 (en) | 2016-06-24 | 2025-10-01 | Infinity Pharmaceuticals Inc | PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
| GB9807903D0 (en) * | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| EP1119368A2 (en) * | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
| WO2001005767A1 (en) * | 1999-07-20 | 2001-01-25 | Novartis Ag | Organic compounds |
| EP1259484B1 (en) * | 2000-01-18 | 2005-05-18 | Novartis AG | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
-
2007
- 2007-04-12 BR BRPI0710723-4A patent/BRPI0710723A2/pt not_active IP Right Cessation
- 2007-04-12 US US12/297,158 patent/US20090306149A1/en not_active Abandoned
- 2007-04-12 RU RU2008144805/14A patent/RU2008144805A/ru not_active Application Discontinuation
- 2007-04-12 KR KR1020087024972A patent/KR20090006089A/ko not_active Withdrawn
- 2007-04-12 WO PCT/US2007/009138 patent/WO2007120827A2/en not_active Ceased
- 2007-04-12 EP EP07755420A patent/EP2010170A2/en not_active Withdrawn
- 2007-04-12 MX MX2008013204A patent/MX2008013204A/es not_active Application Discontinuation
- 2007-04-12 CA CA002648196A patent/CA2648196A1/en not_active Abandoned
- 2007-04-12 AU AU2007238676A patent/AU2007238676A1/en not_active Abandoned
- 2007-04-12 JP JP2009505499A patent/JP2009536156A/ja not_active Withdrawn
- 2007-04-12 CN CNA2007800134377A patent/CN101420949A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536156A5 (enExample) | ||
| B. Johung et al. | Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets | |
| Skowron et al. | Genetic and molecular alterations across medulloblastoma subgroups | |
| Duxbury et al. | Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells | |
| Komarova et al. | Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors | |
| Ju et al. | Oncogenic KRAS promotes malignant brain tumors in zebrafish | |
| CN115215808B (zh) | 用于治疗癌症的组合物和方法 | |
| Morry et al. | Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform | |
| Hackl et al. | Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition | |
| JP2015520753A5 (enExample) | ||
| ES2743507T3 (es) | Inmunoterapia resistente a fármaco para el tratamiento de un cáncer | |
| JP2017514806A5 (enExample) | ||
| JP2018062523A5 (enExample) | ||
| Cruickshanks et al. | Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1 | |
| JP2020515582A5 (enExample) | ||
| Dean | Cancer stem cells: implications for cancer causation and therapy resistance | |
| Ghassemifar et al. | MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells | |
| US20120238518A1 (en) | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | |
| Oliver et al. | Resistance to apoptosis is increased during metastatic dissemination of colon cancer | |
| CN107233340B (zh) | 芳香环类药物在抑制恶性黑色素瘤关键转录因子方面的应用 | |
| ES2978159T3 (es) | Inhibidores de factores de choque térmico (HSF) y usos de los mismos | |
| US20210137898A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
| WO2014106763A1 (en) | Pyridopyrazines as anticancer agents | |
| US20240398788A1 (en) | Methods of treating cancer using hsf1 pathway inhibitors | |
| Lambo et al. | MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY |